PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Am Chem Soc. Author manuscript; available in PMC Jun 16, 2012.
Published in final edited form as:
PMCID: PMC3133816
NIHMSID: NIHMS259179
Light-regulation of protein dimerization and kinase activity in living cells using photocaged rapamycin and engineered FKBP
Andrei V. Karginov,1 Yan Zou,2 David Shirvanyants,3 Pradeep Kota,3 Nikolay V. Dokholyan,3 Douglas D. Young,2 Klaus M. Hahn,1* and Alexander Deiters2*
1Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599
2Department of Chemistry, North Carolina State University, Raleigh, NC 27695
3Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599
alex_deiters/at/ncsu.edu, khahn/at/med.unc.edu
Abstract
An external file that holds a picture, illustration, etc.
Object name is nihms259179f5.jpg Object name is nihms259179f5.jpg
We developed a new system for light-induced protein dimerization in living cells using a novel photocaged analog of rapamycin (pRap) together with an engineered rapamycin binding domain (iFKBP). Using focal adhesion kinase as a target, we demonstrated successful light-mediated regulation of protein interaction and localization in living cells. Modification of this approach enabled light-triggered activation of a protein kinase and initiation of kinase-induced phenotypic changes in vivo.
Rapamycin (Rap, Figure 1a), also known as sirolimus, is a complex macrolide natural product isolated from the bacterium Streptomyces hygroscopicus, found in a soil sample on Easter Island in 1975.14 Rapamycin mediates heterodimerization of the proteins FKBP12 (FK506 binding protein 12) and FRB (FKBP12 rapamycin binding domain).1 Due to rapamycin’s excellent physiological properties, including good pharmacokinetics, permeability across the blood-brain barrier, and oral bioavailability,2 it has been used as a small molecule dimerizer for a wide range of applications in mammalian cells and organisms.3 Furthermore, the FRB-FKBP12 interaction has proven valuable in a broad range of basic research applications, where it has been engineered to control gene function through rapamycin-induced transcription,4, 5 protein localization,4 protein degradation,6 and DNA recombination.7 We recently showed that rapamycin can control kinase activity when an engineered version of FKBP is inserted at a conserved position in the kinase active site8. Thus, a photo-activatable analog of rapamycin represents a unique and important biological research tool, enabling the regulation of heterodimerization and kinase activity using light as a noninvasive regulatory element that can be controlled with high spatial and temporal resolution.
Figure 1
Figure 1
Photocaging of rapamycin. (a) Structure of rapamycin (Rap) and its synthetic transformation into caged rapamycin (pRap) through selective acylation of the C-40 hydroxyl group with nitro-piperonyloxycarbonyl N-hydroxysuccinimide carbonate (NPOC-NHS). (b) (more ...)
Photo-activatable derivatives of small molecules are typically generated through the installation of a light-removable protecting group, a so called “caging group”, at a site crucial for biological activity of the small molecule.9 This renders the molecule inactive, until the caging group is removed through light-irradiation, typically with UV light of 365–405 nm.10 The feasibility of this approach has been demonstrated through successful photochemical regulation of numerous small molecules in cellular environments and multicellular organisms.9, 11 Here, we report the synthesis of a photocaged rapamycin analog (pRap, Figure 1a) which, together with an engineered FKBP (iFKBP), enables successful photo-control of the FKBP-FRB interaction (Figure 1b). The caged rapamycin is applied to regulate both protein dimerization and kinase activity in live cells. Interestingly, caging is not effective with unaltered FKBP, but requires the FKBP mutations described here. An analysis of the chemically accessible sites of rapamycin (Rap) revealed that the methoxy group on C-16 can undergo nucleophilic substitution1317 and β-elimination.12 The hydroxyl groups at C-28 and C-40 can be protected with silyl groups,13,14 and a trifluoromethylsulfonyl group.15 The lactone at C-34 can be hydrolyzed and eliminated22–24 and, importantly, the hydroxyl group at C-40 can be converted into a carbonate group15 and be esterified.15, 20, 21 Thus, C-40 represents the most suitable site for chemical modification with a carbonate-linked caging group that can provide facile installation and quick photolysis. Importantly, based on the crystal structure of the ternary complex of rapamycin, FRB, and FKBP12, the hydroxyl group at C-40 undergoes hydrogen bond formation with the glutamine 53 of FKBP12 (Figure 1c).16 Thus, we hypothesized that disruption of that hydrogen bond through installation of a sterically demanding α-methyl-6-nitropiperonyloxycarbonyl (MeNPOC) group would prevent protein dimerization.
The caged rapamycin pRap was synthesized in one step from rapamycin (Rap) via chemoselective acylation with the mixed carbonate of 6-nitro-piperonyl alcohol and N-hydroxysuccinimide (NPOC-NHS, Figure 1a). The identity of purified pRap was confirmed by 1H NMR and HRMS analysis (see Supporting Information).
We first tested whether pRap could induce dimerization of FKBP12 and FRB. For this we created a GFP-FRB protein fusion and wild-type FKBP12 fused to the N-terminus of focal adhesion kinase (FAK). FAK localizes prominently to focal adhesions in living cells,17 allowing us to test dimerization in vivo by observing rapamycin-mediated translocation of GFP-FRB into focal adhesions. Prior to live cell co-localization studies, the constructs were tested in pull-down assays, comparing the ability of pRap and Rap to mediate the intracellular dimerization of FKBP-FAK and FRB. Cells expressing both FKBP-FAK and FRB were treated with rapamycin or pRap for one hour, with or without irradiation. Complex formation was assayed by pulling down myc-FKBP-FAK from cell lysates and blotting for GFP-FRB (Supporting Figure 1a, b). Surprisingly, both small molecules generated dimerization with similar effectiveness, with or without UV irradiation (Supporting Figure 1a, b). These results were further confirmed by an mTOR activity assay (Supporting Figure 2). This data showed that the FKBP12-rapamycin-FRB complex was not sufficiently sensitive to rapamycin modification for a successful light-activation approach through photocaging.
We hypothesized that alteration of FKBP12 could be used to render the ternary rapamycin-FKBP-FRB interaction more sensitive to the functional groups of pRap affected by photolysis. We tested a recently developed modified FKBP, named iFKBP, that is proposed to have increased structural mobility of the Lys52-Glu54 loop positioned next to the C-40 hydroxyl group of rapamycin (Figure 1c).8 Using both an N-terminal iFKBP-FAK fusion (as tested above for FKBP) and a fusion of iFKBP internally, at position 413 of FAK (Figure 2a), we examined whether pRap could mediate heterodimerization of iFKBP and FRB in a light dependent manner. Indeed, pRap (at concentrations of up to 20 µM) failed to mediate interaction between iFKBP-FAK and GFP-FRB, while irradiation of pRap-treated cells with 365 nm UV light successfully removed the caging group and induced iFKBP-FRB dimerization (Figure 2b–d). Uncaging kinetics were dependent on both light dosage and pRap concentration. Importantly, in the presence of pRap, translocation of FRB into focal adhesions was observed only upon decaging, indicating successful protein dimerization between FAK-iFKBP and FRB in live cells (Figure 2e–f). These studies demonstrated that pRap can effectively mediate light-dependent protein heterodimerization when used with iFKBP rather than FKBP12.
Figure 2
Figure 2
Light-regulated dimerization of iFKBP and FRB. (a) Positions of iFKBP insertions into FAK. (b–d) HEK293T cells co-transfected with GFP-FRB and either myc-iFKBP-FAK (b, c) or myc-FAK-iFKBP413 (d) were treated with either rapamycin (0.5 µM) (more ...)
Recently, we developed a new method for the regulation of protein kinases in live cells.8 Insertion of iFKBP at a structurally conserved position within the catalytic domain of several kinases, including FAK, rendered the kinases inactive. Our previous studies indicate that insertion of the iFKBP increases the mobility of the critical G-loop in the catalytic domain of FAK, resulting in the inhibition of catalytic activity.8 Formation of iFKBP-rapamycin-FRB complex through addition of rapamycin significantly restricts iFKBP dynamics, thus stabilizing the G-loop and rescuing the kinase activity.8 This was used to achieve specific control of kinases in living cells with high temporal resolution.8
Here we tested the light-mediated regulation of FAK activity with pRap using RapR-FAK (rapamycin-regulated FAK) as a model (Figure 3a). Myc-tagged RapR-FAK was co-expressed with GFP-FRB in HEK293T cells. As in the published validation of RapR-FAK, we examined rapamycin’s ability to induce RapR-FAK phosphorylation of the N-terminal fragment of paxillin,18 a signal transduction adaptor protein and natural FAK substrate. Unlike rapamycin, pRap was completely inactive at concentrations of up to 20 µM, producing no detectable paxillin Tyr31 phosphorylation. UV irradiation alone did not activate RapR-FAK in the absence of pRap, but irradiation in the presence of pRap (1–20 µM) induced activation of RapR-FAK through protein complex formation with FRB (Figure 3b), leading to robust phosphorylation of paxillin. Light-mediated interaction between RapR-FAK and GFP-FRB was further confirmed by co-immunoprecipitation of the two proteins (Figure 3b) and by translocation of FRB to focal adhesions (Figure 2f) upon pRap irradiation.
Figure 3
Figure 3
Light-mediated activation of a protein kinase. (a) Schematic of RapR-FAK regulation by pRap. (b) Myc-RapR-FAK kinase was co-expressed with GFP-FRB in HEK293T cells. Cells were treated with the indicated amount of rapamycin (Rap), caged rapamycin (pRap (more ...)
Finally, we examined whether light induced activation of pRap could be used to control cell behavior. FAK activation has been shown to produce large dorsal membrane ruffles8. We therefore examined effects of RapR-FAK activation on the membrane dynamics of HeLa cells. In the presence of pRap, but without UV irradiation, transfected HeLa cells displayed normal, small peripheral ruffles around the border of the cell (Figure 3c), consistent with inactive RapR-FAK. In contrast, UV irradiation (365 nm) produced very large and dynamic ruffles across the dorsal cell surface (Figure 3d and Supporting Movie 1). This UV-induced phenotype was displayed in 40% of analyzed cells (9 of 22 cells), in excellent agreement with effects of regular rapamycin on RapR-FAK (56% positive cells).8
To explore how modification of FKBP to iFKBP was able to render pRap inactive until irradiated with UV light, we performed discrete molecular dynamics (DMD) simulations.19 Within the sampled conformations we identified the dominant ensemble and compared the localization of residues that form the iFKBP-FRB and FKBP12-FRB interfaces. Surprisingly, our simulations demonstrated that binding of the caged rapamycin to iFKBP is at least as strong as that to FKBP12, but the interaction of the added piperonyloxycarbonyl moiety with iFKBP distorts the protein’s binding-competent conformations and prevents binding of FRB. The most notable difference between the iFKBP and FKBP complexes is a significant distortion of the FRB-binding interface formed by the segment Asp41-Leu49 (Figure 4a–b; Supporting Movies 25). The interface area formed between pRap and iFKBP is larger than that between pRap and FKBP12. Due to its higher structural plasticity, the iFKBP protein is able to deform and create additional contacts with pRap, which is unachievable by the more rigid and stable FKBP12. Based on these simulations, we suggest that strong binding between iFKBP and pRap distorts the FRB-binding interface in FKBP12, and thus prevents further binding to FRB.
Figure 4
Figure 4
Molecular dynamics simulations of the FKBP12-pRap-iFKBP interaction. (a) Tube representations of FKBP12 (left) and iFKBP (right) with pRap in the binding pocket. Warmer colors and thicker backbones correspond to fluctuations within the structure. Note (more ...)
In summary, we have developed a new photocaged analog of rapamycin, pRap, which can be used together with iFKBP, an engineered version of FKBP12, for the light-mediated regulation of protein dimerization. We demonstrated successful use of this new dimerization system by modulating protein interactions for two different FAK-iFKBP fusions in living cells. Furthermore, we achieved light-mediated activation of an engineered protein kinase, FAK, and demonstrated light-induced changes in cell behavior characteristic of this kinase. Rapamycin-mediated protein dimerization and regulation of kinases have lacked the precise spatial and temporal control of light-mediated processes. Our new caged rapamycin approach will significantly enhance the many existing methodologies that use rapamycin for the regulation of protein activity in cells and multicellular organisms. We are currently exploring the synthesis of caged, orthogonal rapalogs and two-photon activated caged rapamycin.
Supplementary Material
1_si_001
2_si_002
3_si_003
4_si_004
5_si_005
6_si_006
Acknowledgement
This research was supported by the NIH (AD, GM079114; KH, cell migration consortium grant GM64346; NVD, GM080742 and the ARRA supplements GM080742-03S1 and GM066940-06S1).
Footnotes
Supporting Information Available. Synthetic protocols and proton NMR spectrum of caged rapamycin, protocols for cell culture experiments, supporting movies, and detailed information on the molecules dynamics simulations. This information is available free of charge via the World Wide Web at http://pubs.acs.org.
1. Huang S, Bjornsti MA, Houghton PJ. Cancer Biol Ther. 2003;2:222. [PubMed]
2. Abraham RT, Wiederrecht GJ. Annu Rev Immunol. 1996;14:483. [PubMed]
3. Pollock R, Clackson T. Curr. Opin. Biotechnol. 2002;13:459. [PubMed]
4. Bayle JH, Grimley JS, Stankunas K, Gestwicki JE, Wandless TJ, Crabtree GR. Chem Biol. 2006;13:99. [PubMed]
5. Pollock R, Issner R, Zoller K, Natesan S, Rivera VM, Clackson T. Proc. Natl. Acad. Sci. U. S. A. 2000;97:13221. [PubMed]
6. (a) Edwards SR, Wandless TJ. J. Biol. Chem. 2007;282:13395. [PubMed] (b) Maynard-Smith LA, Chen LC, Banaszynski LA, Ooi AG, Wandless TJ. J. Biol. Chem. 2007;282:24866. [PubMed]
7. Keith CT, Schreiber SL. Science. 1995;270:50. [PubMed]
8. Karginov AV, Ding F, Kota P, Dokholyan NV, Hahn KM. Nat Biotechnol. 2010 [PMC free article] [PubMed]
9. (a) Riggsbee CW, Deiters A. Trends Biotechnol. 2010;28:468. [PubMed] (b) Mayer G, Heckel A. Angew Chem Int Ed Engl. 2006;45:4900. [PubMed] (c) Young DD, Deiters A. Org Biomol Chem. 2007;5:999. [PubMed] (d) Deiters A. Chembiochem. 2010;11:47. [PubMed] (e) Deiters A. Curr Opin Chem Biol. 2009;13:678. [PubMed] (f) Tang X, Dmochowski IJ. Mol Biosyst. 2007;3:100. [PubMed] (g) Lawrence DS. Curr Opin Chem Biol. 2005;9:570. [PubMed] (h) Curley K, Lawrence DS. Curr Opin Chem Biol. 1999;3:84. [PubMed] (i) Lee HM, Larson DR, Lawrence DS. ACS Chem Biol. 2009;4:409. [PubMed] (j) Dorman G, Prestwich GD. Trends Biotechnol. 2000;18:64. [PubMed] (k) Adams SR, Tsien RY. Annu Rev Physiol. 1993;55:755. [PubMed]
10. (a) Dong Q, Svoboda K, Tiersch TR, Monroe WT. J Photochem Photobiol B. 2007;88:137. [PubMed] (b) Schindl A, Klosner G, Honigsmann H, Jori G, Calzavara-Pinton PC, Trautinger F. J Photochem Photobiol B. 1998;44:97. [PubMed] (c) Robert C, Muel B, Benoit A, Dubertret L, Sarasin A, Stary A. J. Invest. Dermatol. 1996;106:721. [PubMed]
11. (a) Goard M, Aakalu G, Fedoryak OD, Quinonez C, St Julien J, Poteet SJ, Schuman EM, Dore TM Chem Biol. 2005;12:685. [PubMed] (b) Cambridge SB, Geissler D, Calegari F, Anastassiadis K, Hasan MT, Stewart AF, Huttner WB, Hagen V, Bonhoeffer T Nat Methods. 2009;6:527. [PubMed] (c) Sauers DJ, Temburni MK, Biggins JB, Ceo LM, Galileo DS, Koh JT ACS Chem Biol. 2010;5:313. [PubMed] (d) Young DD, Garner RA, Yoder JA, Deiters A Chem Commun. 2009:568. [PMC free article] [PubMed] (e) Young DD, Deiters A Angew. Chem. Int. Ed. 2007;46:4290. [PubMed] (f) Link KH, Cruz FG, Ye HF, O'Reilly KE, Dowdell S, Koh JT Bioorg Med Chem. 2004;12:5949. [PubMed] (g) Cruz FG, Koh JT, Link KH J. Am. Chem. Soc. 2000;122:8777. Over the course of our studies a C16 caged rapamycin has been reported: (h) Sadovski O, Jaikaran AS, Samanta S, Fabian MR, Dowling RJ, Sonenberg N, Woolley GA Bioorg. Med. Chem. 2010;18:7746. [PubMed] Interestingly, a previously synthesized C16 nitrobenzyl caged rapamycin was fully active in our assays.
12. Grinfeld AA, Caufield CE, Schiksnis RA, Mattes JF, Chan KW. Tetrahedron Lett. 1994;35:6835.
13. Nelson FC, Stachel SJ, Mattes JF. Tetrahedron Lett. 1994;35:7557.
14. Ayral-Kaloustian S, Gu JX, Lucas J, Cinque M, Gaydos C, Zask A, Chaudhary I, Wang JY, Di L, Young M, Ruppen M, Mansour TS, Gibbons JJ, Yu K. J. Med. Chem. 2010;53:452. [PubMed]
15. Wagner R, et al. Bioorg. Med. Chem. Lett. 2005;15:5340. [PubMed]
16. (a) Choi J, Chen J, Schreiber SL, Clardy J. Science. 1996;273:239. [PubMed] (b) Liang J, Choi J, Clardy J. Acta Crystallogr D Biol Crystallogr. 1999;55:736. [PubMed]
17. Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT. Proc. Natl. Acad. Sci. U. S. A. 1992;89:5192. [PubMed]
18. (a) Deakin NO, Turner CE. J. Cell Sci. 2008;121:2435. [PubMed] (b) Schaller MD. J. Cell Biol. 2004;166:157. [PubMed]
19. (a) Dokholyan NV, Buldyrev SV, Stanley HE, Shakhnovich EI. Fold Des. 1998;3:577. [PubMed] (b) Ding F, Tsao D, Nie H, Dokholyan NV. Structure. 2008;16:1010. [PubMed]